Celcuity

Celcuity developed gedatolisib, approved in July 2026 for hormone-positive breast cancer.

Gedatolisib (Revtorpyk, pan-PI3K/mTOR) with palbociclib and fulvestrant; VIKTORIA-1 and VIKTORIA-2 trials.

Headquarters

Minneapolis, MN, US

Type

biotech · CELC

Website

Products

An intravenous drug that blocks the whole PI3K/mTOR pathway, approved in July 2026 for hormone-positive breast cancer.

not linked directly; found by shared links